Nong Shang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nong Shang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Arnstein Lindaas
Acumen, LLC, 500 Airport Blvd. Suite 100, Burlingame, CA 94010, United States
2 shared publications - Bradley Lufkin
Acumen, LLC , Burlingame, California
2 shared publications - Gordana Derado
Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention , Atlanta, GA
2 shared publications - J. Steven Kammerer
Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA, USA
2 shared publications - Kristin L. Andrejko
Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, GA 30329
2 shared publications - Lindsay Zielinski
Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia
2 shared publications
Latest Publications
- 15 November 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (3) , e840-e841
Letter to the Editor in Response to Zhao et al
- 15 November 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (3) , e840-e841
Letter to the Editor in Response to Zhao et al
- 2 August 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (6) , e953-e961
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Pneumonia Hospitalization Among Medicare Beneficiaries Aged ≥65 Years in Long-Term Care
Background: Pneumonia causes high rates of hospitalization among adults living in long-term care (LTC) facilities and is a major cause of mortality in this population. Since 2014, pneumococcal conjugate vaccines (PCVs) have been recommended for US adults aged ≥65 years; however, effectiveness of PCVs against all-cause pneumonia hospitalization among adults living in LTC remains unclear. Methods: We used Medicare Fee-for-Service claims data to construct an open cohort of beneficiaries aged ≥65 years between September 2014 and December 2019. We estimated 13-valent PCV (PCV13) vaccine effectiveness (VE) by comparing rates of pneumonia hospitalization among PCV13-exposed and PCV13-unexposed time during LTC stays. Discrete-time logistic regression models with generalized estimating equations were used to estimate VE, incorporating time-varying exposures and covariates. Results: Among 3 485 071 beneficiaries meeting the eligibility criteria, the proportion vaccinated with PCV13 increased from 1.1% to 52.7% during the study period. The characteristics of beneficiaries with shorter LTC stays differed from those with longer LTC stays: a lower proportion of beneficiaries aged ≥85 years (LTC stay ≤100 vs >100 days: 38.5% vs 48.2%), but a higher proportion with chronic medical conditions (71.4% vs 66.4%), immunocompromising conditions (36.6% vs 25.2%), and recent hospitalizations (84.1% vs 74.7%). Vaccine effectiveness of PCV13 only against all-cause pneumonia hospitalization was 3.8% (95% CI 2.4%–5.2%) overall: 5.6% (3.9%–7.2%) for LTC stays ≤100 days and 0.3% (−2.1%–2.77%) for LTC stays >100 days. Conclusions: 13-Valent PCV reduced the risk of pneumonia hospitalization among this population. Differences in beneficiary characteristics could explain differences in VE by length of LTC stay.
- 2 August 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (6) , e953-e961
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Pneumonia Hospitalization Among Medicare Beneficiaries Aged ≥65 Years in Long-Term Care
Background: Pneumonia causes high rates of hospitalization among adults living in long-term care (LTC) facilities and is a major cause of mortality in this population. Since 2014, pneumococcal conjugate vaccines (PCVs) have been recommended for US adults aged ≥65 years; however, effectiveness of PCVs against all-cause pneumonia hospitalization among adults living in LTC remains unclear. Methods: We used Medicare Fee-for-Service claims data to construct an open cohort of beneficiaries aged ≥65 years between September 2014 and December 2019. We estimated 13-valent PCV (PCV13) vaccine effectiveness (VE) by comparing rates of pneumonia hospitalization among PCV13-exposed and PCV13-unexposed time during LTC stays. Discrete-time logistic regression models with generalized estimating equations were used to estimate VE, incorporating time-varying exposures and covariates. Results: Among 3 485 071 beneficiaries meeting the eligibility criteria, the proportion vaccinated with PCV13 increased from 1.1% to 52.7% during the study period. The characteristics of beneficiaries with shorter LTC stays differed from those with longer LTC stays: a lower proportion of beneficiaries aged ≥85 years (LTC stay ≤100 vs >100 days: 38.5% vs 48.2%), but a higher proportion with chronic medical conditions (71.4% vs 66.4%), immunocompromising conditions (36.6% vs 25.2%), and recent hospitalizations (84.1% vs 74.7%). Vaccine effectiveness of PCV13 only against all-cause pneumonia hospitalization was 3.8% (95% CI 2.4%–5.2%) overall: 5.6% (3.9%–7.2%) for LTC stays ≤100 days and 0.3% (−2.1%–2.77%) for LTC stays >100 days. Conclusions: 13-Valent PCV reduced the risk of pneumonia hospitalization among this population. Differences in beneficiary characteristics could explain differences in VE by length of LTC stay.
- Open Access
Covariate Adjusted Logit Model (CALM) for Generating Dose-Response Curves from Observational Data with Applications to Vaccine Effectiveness Trials
Establishing dose-response relationships from observational data is challenging due to confounding and sample selection bias. Standard causal methods adjust for confounding but typically require knowledge of covariate distributions in the target population—often via a well-defined probability sampling scheme. We propose the Covariate Adjusted Logit Model (CALM), which generalizes log-linear structural mean models for binary exposures to continuous exposures by modeling a relative dose-response curve anchored to a baseline level. By separating this curve from the null disease risk (NDR) at baseline, CALM enables valid inference under biased sampling while adjusting for confounding effects. A Gibbs sampler—the All-or-Nothing algorithm—is introduced to support Bayesian modeling, drawing on a vaccine-effect-inspired interpretation of the relative dose-response curve. Simulation studies demonstrate that CALM recovers dose-response relationships more accurately in the presence of bias and confounding. In vaccine trials, where confounding covariates affect immune responses differently across study arms, CALM provides a more accurate and robust antibody–disease curve to serve as a surrogate for evaluating vaccine effectiveness.
Open AccessCovariate Adjusted Logit Model (CALM) for Generating Dose-Response Curves from Observational Data with Applications to Vaccine Effectiveness Trials
Establishing dose-response relationships from observational data is challenging due to confounding and sample selection bias. Standard causal methods adjust for confounding but typically require knowledge of covariate distributions in the target population—often via a well-defined probability sampling scheme. We propose the Covariate Adjusted Logit Model (CALM), which generalizes log-linear structural mean models for binary exposures to continuous exposures by modeling a relative dose-response curve anchored to a baseline level. By separating this curve from the null disease risk (NDR) at baseline, CALM enables valid inference under biased sampling while adjusting for confounding effects. A Gibbs sampler—the All-or-Nothing algorithm—is introduced to support Bayesian modeling, drawing on a vaccine-effect-inspired interpretation of the relative dose-response curve. Simulation studies demonstrate that CALM recovers dose-response relationships more accurately in the presence of bias and confounding. In vaccine trials, where confounding covariates affect immune responses differently across study arms, CALM provides a more accurate and robust antibody–disease curve to serve as a surrogate for evaluating vaccine effectiveness.
- Open Access
- 1 January 2013
- Published by Springer Nature in International Journal of Health Geographics
- Vol. 12 (1) , 15
Using statistical methods and genotyping to detect tuberculosis outbreaks
Early identification of outbreaks remains a key component in continuing to reduce the burden of infectious disease in the United States. Previous studies have applied statistical methods to detect unexpected cases of disease in space or time. The objectives of our study were to assess the ability and timeliness of three spatio-temporal methods to detect known outbreaks of tuberculosis.
- 1 January 2013
- Published by Springer Nature in International Journal of Health Geographics
- Vol. 12 (1) , 15
Open AccessUsing statistical methods and genotyping to detect tuberculosis outbreaks
Early identification of outbreaks remains a key component in continuing to reduce the burden of infectious disease in the United States. Previous studies have applied statistical methods to detect unexpected cases of disease in space or time. The objectives of our study were to assess the ability and timeliness of three spatio-temporal methods to detect known outbreaks of tuberculosis.
- 1 February 2005
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 28 (2) , 201-207
Tuberculosis transmission in nontraditional settings
- 1 February 2005
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 28 (2) , 201-207
Tuberculosis transmission in nontraditional settings